DBV Technologies (NASDAQ:DBVT) PT Raised to $7.00

DBV Technologies (NASDAQ:DBVT) had its price objective upped by HC Wainwright from $5.00 to $7.00 in a report published on Thursday, Benzinga reports. The firm currently has a buy rating on the stock. HC Wainwright also issued estimates for DBV Technologies’ FY2024 earnings at ($1.41) EPS, FY2027 earnings at ($1.06) EPS and FY2028 earnings at ($0.50) EPS.

Other analysts have also issued reports about the company. StockNews.com initiated coverage on DBV Technologies in a report on Monday, October 21st. They set a “hold” rating on the stock. JMP Securities reiterated a “market outperform” rating and set a $5.00 price objective on shares of DBV Technologies in a research note on Tuesday, September 24th.

DBV Technologies Stock Up 3.5 %

Shares of DBV Technologies stock opened at $0.87 on Thursday. The company has a 50-day simple moving average of $0.77 and a two-hundred day simple moving average of $0.95. DBV Technologies has a twelve month low of $0.50 and a twelve month high of $2.28. The stock has a market capitalization of $83.61 million, a price-to-earnings ratio of -1.03 and a beta of 0.67.

DBV Technologies (NASDAQ:DBVT) last released its quarterly earnings results on Tuesday, July 30th. The company reported ($0.34) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.26) by ($0.08). The business had revenue of $1.16 million during the quarter, compared to analyst estimates of $1.42 million. DBV Technologies had a negative net margin of 638.21% and a negative return on equity of 74.41%. During the same quarter in the previous year, the firm posted ($0.26) earnings per share. On average, sell-side analysts anticipate that DBV Technologies will post -1.43 earnings per share for the current fiscal year.

Institutional Trading of DBV Technologies

An institutional investor recently raised its position in DBV Technologies stock. Yiheng Capital Management L.P. lifted its stake in shares of DBV Technologies S.A. (NASDAQ:DBVT) by 6.2% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 5,568,909 shares of the company’s stock after purchasing an additional 327,345 shares during the quarter. DBV Technologies accounts for about 0.2% of Yiheng Capital Management L.P.’s portfolio, making the stock its 15th largest position. Yiheng Capital Management L.P. owned about 2.89% of DBV Technologies worth $4,172,000 as of its most recent filing with the Securities and Exchange Commission. Institutional investors own 71.74% of the company’s stock.

About DBV Technologies

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow’s milk protein allergy and eosinophilic esophagitis.